Startup · $2.1m raised
Programs: Brandon BioCatalyst (CUREator+) · CUREator+ (CUREator+)
Every investor coverage indicates participated in a round Navier Medical Ltd raised.
| Investor | Rounds | Invested |
|---|---|---|
| CUREator+ | Accelerator · Grant | - |
| Brandon BioCatalyst | Accelerator · Grant | - |
Companies Navier Medical Ltd acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Sander Bangma | CEO | Dealroom |
Stories naming Navier Medical Ltd. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Six Australian health tech startups received non-dilutive grants totaling $13.5 million from the government-backed CUREator+ program to accelerate commercialisation of medical innovations.
Six Australian biomedical and health ventures receive a combined $13.5 million in non-dilutive grants through round two of the CUREator+ commercialisation program operated by Brandon BioCatalyst and backed by the Medical Research Future Fund.
Also Dealroom
Six Australian health tech startups received a combined $13.5 million in non-dilutive funding from the CUREator+ program, supported by the Australian Government.
CUREator+ granted thirteen point five million dollars in non-dilutive funding to six Australian health tech startups to support commercialisation of medical innovations.